16 July 2018
JAD is pleased to announce that Greg Kennedy, a PhD candidate at the Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Australia, has been chosen as the recipient of the 2018 Alzheimer Award.
20 June 2018
Ground-breaking new research has identified a unique combination of nutrients to slow the progression of Alzheimer’s Disease (AD), which affects over 520,000 people in the UK and represents a burden on the struggling NHS of over £26 billion per year. The 18-month study, published in the June edition of the respected Journal of Alzheimer’s Disease (JAD), examined the effect of nutritional compounds - found in common foods such as trout, broccoli, and peppers on people with the condition, and unveiled a ‘statistically significant’ find.
19 June 2018
An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most benefit from Deep Brain Stimulation of the fornix (DBS-f), as observed in the data from the phase 2 findings (12 – 24 months) of the Phase II trial.
12 June 2018
The rate of decline in certain aspects of memory may be explained by a combination of overall physical fitness and the stiffness of the central arteries, researchers from Swinburne’s Centre for Human Psychopharmacology have found. A study to be published in the Journal of Alzheimer’s Disease considers the mechanisms underlying cognitive performance in older people living independently. Lead author, PhD candidate Greg Kennedy, says that from early adulthood, memory and other aspects of cognition slowly decline, with an increasing risk of developing into dementia in later life.
8 May 2018
Body-worn sensors used at home and in clinic by people with mild Alzheimer’s to assess walking could offer a cost-effective way to detect early disease and monitor progression of the illness. A pilot study involving Newcastle University has revealed low-cost wearable devices could improve clinical trial efficiency and encourage research investment.
1 May 2018
Journal of Alzheimer’s Disease marks its 20th anniversary with a milestone issue covering 20 years of Alzheimer's research
IOS Press is pleased to announce that 2018 marks the 20th anniversary of the Journal of Alzheimer’s Disease (JAD). One of the many events celebrating this milestone is the publication of an open access issue (JAD 62:3) looking back at 20 years of Alzheimer’s disease (AD) research, which is now available online.
24 April 2018
What if you could know that your mild cognitive impairment wouldn't progress in the next decade through the result of two simple neuropsychological tests?
Researchers from the Lisbon School of Medicine, University of Lisbon found that, in some mild cognitive impairment patients, real neuropsychological stability over a decade is possible and that long-term stability could be predicted based on neuropsychological tests measuring memory and non-verbal abstract reasoning.
23 April 2018
Late, but not too late – Screening for olfactory dysfunction as a marker for cognitive impairment in middle-aged
In a large population-based study of randomly selected participants in Germany, researchers found that participants aged 65-74 years with olfactory dysfunction showed impaired cognitive performance. Interestingly, this strong association was not present in younger (55-64 years) or older (75-86 years) participants. Additionally, the effect was more present in women than men.
28 March 2018
Columbia University neurologist William Kreisl, MD, has been studying a smell identification test and explains what it can – and can’t – say about Alzheimer's. His most recent study appears in the Journal of Alzheimer’s Disease. Here, he provides further explanation about his research.
27 March 2018
Detecting diminished dopamine-firing cells inside the brain could reveal earliest signs of Alzheimer’s disease
Sheffield scientists discover a loss of cells that use dopamine may cause part of the brain - responsible for forming new memories - to function less effectively. These findings could revolutionise screening for Alzheimer’s disease, which affects more than 520,000 people in the UK.